Two ingredients are given separately: one is placed at or guided to the tumour, the other is an inactive form of a cancer drug sent through the blood. Where they meet, a fast chemical reaction releases the active drug. One early trial in people showed the chemistry works in the body but did not shrink more tumours than the ordinary drug.
Click-activated prodrugs split a cancer medicine into two parts that do nothing alone. An activator is first put at the tumour, either by injecting it into a lesion or by attaching it to something that binds a tumour antigen. An inert, chemically capped form of a cytotoxic drug is then given into a vein. The two carry matched reactive groups, a tetrazine and a trans-cyclooctene, which react with each other and with little else in the body (a bioorthogonal, or click, reaction). In the published designs the reaction captures the capped drug at the activator and the cap then falls away, releasing the active drug at that site.
The chemistry was recognised by the 2022 Nobel Prize in Chemistry, awarded to Carolyn Bertozzi, Morten Meldal and Barry Sharpless for the development of click chemistry and bioorthogonal chemistry; the prize announcement noted that bioorthogonal reactions were being used to improve the targeting of cancer medicines in clinical trials.
The first reported use in patients was Shasqi's SQ3370: a tetrazine-modified hyaluronate biopolymer injected into one tumour, followed by daily infusions of a trans-cyclooctene-modified doxorubicin. Its phase 1/2a trial (NCT04106492) gave doxorubicin-equivalent doses up to 15 times the conventional dose per cycle with no protocol-defined dose-limiting toxicity, and the authors measured rapid release of active doxorubicin at every dose level. In the 14 patients with soft tissue sarcoma treated in phase 2a, two had an unconfirmed objective response (14.3 per cent), which the authors describe as comparable to standard doxorubicin, and the trial was stopped because the prespecified bar of a response rate above standard doxorubicin was not met. So the trial supports the chemistry and the tolerability, and does not show better tumour control.
A second form replaces the injected biopolymer with a tumour-binding protein carrying the activator, which removes the need for an injectable lesion. Shasqi has published this in mice with a HER2-binding antibody fragment and a capped MMAE, and its pipeline lists CEACAM5-targeted programmes that have not reached the clinic. Tagworks Pharmaceuticals uses the reaction the other way round, in an approach it calls Click-to-Release: its TGW101 is a diabody drug conjugate whose payload is cut free by a separately given small-molecule trigger, in a phase 1 trial registered as NCT06959706. No medicine of this kind is approved anywhere.
An inverse electron-demand Diels-Alder reaction between a tetrazine and a trans-cyclooctene (TCO). In Shasqi's design the tetrazine sits on the tumour-localised activator and the TCO caps the drug, attenuating its activity; the reaction at the tumour captures the capped drug and is followed by release of the native drug. Activation depends on the two components meeting, not on tumour enzymes, acidity, oxygen level or uptake into the cell.
SQ3370 is an experimental two-part treatment from Shasqi: a gel injected into a tumour, then an inactive form of the chemotherapy drug doxorubicin given into a vein, which the gel switches on. In its one trial, very high doses caused no dose-limiting side effects, but tumours responded no more often than with ordinary doxorubicin and the trial was stopped. It is not approved anywhere.
It establishes that a click reaction between two separately given substances can be run inside a person, and that capping doxorubicin this way lets far more of it be given. It does not establish that patients do better: the abstract reports no tumour responses, and the trial's phase 2a part later found a response rate comparable to standard doxorubicin.
For a person with sarcoma, this is a treatment that was easier to tolerate than its dose would suggest but did not work better than doxorubicin in the small group tested, and it is not available. For the field, it is the human proof that click activation works as chemistry, which is why the company has moved to versions guided by tumour-binding proteins.
It is the published basis for the antigen-targeted programmes on Shasqi's pipeline, which no longer need a tumour that can be injected. None of these has been tested in people.
It names the two components of SQ3370 and the reaction that joins them, and shows the design is modular: the same activator can switch on different capped drugs.
This is the animal evidence behind the hope that treating one injectable tumour could help disease elsewhere. In the human trial that followed, shrinkage of non-injected lesions was seen, but the overall response rate was no higher than with standard doxorubicin.
This is the origin of the approach, published four years before the first patient was treated.
It shows the capture step working in an animal before any drug was attached to the idea.
Query for this technology: (TITLE:"Click-activated prodrugs" OR ABSTRACT:"Click-activated prodrugs" OR TITLE:"bioorthogonal drug activation in the body" OR ABSTRACT:"bioorthogonal drug activation in the body" OR TITLE:"click chemistry prodrug activation" OR ABSTRACT:"click chemistry prodrug activation" OR TITLE:"bioorthogonal prodrug activation" OR ABSTRACT:"bioorthogonal prodrug activation") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Click-activated prodrugs (bioorthogonal drug activation in the body), not a curated reading list.
Shares Tagworks Pharmaceuticals, Antibody-drug conjugate (ADC) and the tag frontier.
Shares Payload (ADC), Antibody-drug conjugate (ADC) and the tag frontier.
Shares Payload (ADC), Antibody-drug conjugate (ADC) and the tag frontier.
Shares Antibody-drug conjugate (ADC) and the tag frontier.
Shares Cytotoxic chemotherapy and the tag frontier.
Shares Cytotoxic chemotherapy and the tag frontier.
Shares Antibody-drug conjugate (ADC) and the tag frontier.
Shares Cytotoxic chemotherapy and the tag frontier.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/